Translucence Biosystems CEO Damian Wheeler, presented "Brain-Wide Parenchymal Quantification of BBB-Crossing Antibody Therapeutics" during the "Emerging Principles of Anti-TfR Shuttle Engineering" session at the recent Drug Delivery to the Brain: Emerging Modalities Keystone Symposia meeting held on February 17–20, 2025.
During his talk, Dr. Wheeler highlighted recent work by Translucence Biosystems in collaboration with Lundbeck. The work demonstrates how combining tissue clearing methodologies with light sheet fluorescence microscopy enables brain-wide, micron-scale visualization and quantification of next-generation antibody therapeutics for Alzheimer’s disease and other central nervous system (CNS) disorders.
Since the inaugural meeting in 2023, organized by Robert Thorne, interest in BBB-shuttle mechanisms has surged—fueling the development of new modalities for CNS drug delivery.
Translucence Biosystems thanks the event organizers, Stina Syvänen and James Gorman, and appreciated the engaging discussions with researchers exploring tissue clearing as a quantitative approach for antibody therapeutics.
Ask your question
Send us your questions and we will get back to you as soon as possible
info@translucencebio.com
